Development of a long-term in vitro assay able to identify compounds that can overcome resistance to CDK4/6 inhibitor plus endocrine therapy in ER+HER2-breast cancer

被引：0
|
作者：
Kronstadt, Stephanie
Umbreit, Neil
Niederst, Matt
Janssens, Rens
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO5-23-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO5-23-10
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer
    Goetz, M. P.
    Beeram, M.
    Beck, T.
    Conlin, A. K.
    Dees, E. C.
    Dickler, M. N.
    Helsten, T. L.
    Conkling, P. R.
    Edenfield, W. J.
    Richards, D. A.
    Turner, P. K.
    Cai, N.
    Chan, E. M.
    Pant, S.
    Becerra, C. H.
    Kalinsky, K.
    Puhalla, S. L.
    Rexer, B. N.
    Burris, H. A.
    Tolaney, S. M.
    CANCER RESEARCH, 2016, 76
  • [22] Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2-Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies
    Al-Qasem, Abeer J.
    Alves, Carla L.
    Ditzel, Henrik J.
    CANCERS, 2021, 13 (21)
  • [23] Pak1 as a novel mediator of resistance to endocrine therapy and CDK4/6 inhibitors in ER plus /PAK-1amplified breast cancer
    Belli, Stefania
    Servetto, Alberto
    Di Mauro, Concetta
    Esposito, Daniela
    Pesapane, Ada
    Napolitano, Fabiana
    Santaniello, Antonio
    De Placido, Pietro
    Cascetta, Priscilla
    Carratu, Annachiara
    Mozzillo, Eleonora
    Marciano, Roberta
    Bianco, Roberto
    Formisano, Luigi
    CANCER RESEARCH, 2020, 80 (04)
  • [24] CDK4/6 inhibitor plus endocrine therapy for advanced breast cancer: results from a web-based survey in Japan
    Nakayama, Takahiro
    Xu, Linghua
    Muramatsu, Yasuaki
    FUTURE ONCOLOGY, 2025, 21 (03) : 321 - 330
  • [25] A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2-breast cancer
    Servetto, Alberto
    Napolitano, Fabiana
    Angelis, Carmine De
    Placido, Pietro De
    Giuliano, Mario
    Arpino, Grazia
    Placido, Sabino De
    Bianco, Roberto
    Formisano, Luigi
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 157
  • [26] Combining OP-3136, a KAT6 inhibitor, with endocrine therapy and CDK4/6 inhibitor enhances anti-tumor activity in ER+/HER2-breast cancer models
    Palanisamy, G.
    Barratt, S.
    Hope, C.
    Robello, B.
    Pena, G.
    Goyal, M.
    Venkateshappa, C.
    Ng, R.
    Ramachandra, M.
    Myles, D.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S89 - S89
  • [27] Genomic Landscape of ER+/HER2-metastatic breast cancer as a function of prior treatment with a CDK4/6 inhibitor
    Chica-Parrado, M. Rosario
    Chica-Parrado, M. Rosario
    Lin, Chang-Ching
    Mahoney, Timothy
    Mauer, Elizabeth
    Hanker, Ariella
    Arteaga, Carlos
    CANCER RESEARCH, 2023, 83 (05)
  • [28] Gene expression analysis in circulating tumour cells to determine resistance to CDK4/6 inhibitors plus endocrine therapy in HR + /HER2-metastatic breast cancer patients
    Gonzalez-Conde, Miriam
    Yanez, Celso
    Abuin, Carmen
    Keup, Corinna
    Lago-Leston, Ramon
    Aybar, Maribel
    Pedrouzo, Lucia
    Palacios, Patricia
    Curiel, Teresa
    Cueva, Juan
    Rodriguez, Carmela
    Carmona, Marta
    Cortegoso, Alexandra
    Garcia-Caballero, Tomas
    Muinelo-Romay, Laura
    Kasimir-Bauer, Sabine
    Lopez-Lopez, Rafael
    Costa, Clotilde
    JOURNAL OF TRANSLATIONAL MEDICINE, 2025, 23 (01)
  • [29] Multi-omics analysis identifies the mechanism in cross-resistance to endocrine therapy and CDK4/6 inhibitor in breast cancer
    Hou, Ming-Feng
    Li, Chung-Liang
    Chiang, Chih-Po
    CANCER RESEARCH, 2024, 84 (09)
  • [30] Therapy of advanced HR+, HER2-Breast Cancer Live professionally longer with CDK4/6 Inhibitor
    Ruedesheim, Sabine M.
    BREAST CARE, 2021, 16 (03)
12345